Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606

Leukemia Research

Volumn 31, Issue 7, 2007, Pages 979-987

  Mancini, Manuela ^a   Brusa, Gianluca ^a   Zuffa, Elisa ^a   Corrado, Patrizia ^a   Martinelli, Giovanni ^a   Grafone, Tiziana ^a   Barbieri, Enza ^a   Santucci, Maria Alessandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chronic myloid leukemia; Cyclin dependent kinase 2 (Cdk2); p210 tyrosine kinase (TK); Phosphatidylinositol 3 kinase (PI 3k) Akt; SRC kinases

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CYCLIN DEPENDENT KINASE 2; INTERLEUKIN 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE PHOSPHATASE; TYROSINE;

ARTICLE; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANILINE COMPOUNDS; APOPTOSIS; CDC25 PHOSPHATASE; CELL CYCLE; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOID, CHRONIC; NITRILES; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SRC-FAMILY KINASES; TUMOR CELLS, CULTURED;

EID: 34249787619     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.09.022     Document Type: Article

References (48)

1. Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P.K., and Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 344 (1990) 251-253
2. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
3. Konopka J.B., and Witte O.N. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 5 (1985) 3116-3123
4. Kantarjian H.M., Cortes J.E., O'Brien S., Giles F., Garcia-Manero G., Faderl S., et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101 (2003) 97-100
5. Van Etten R.A. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 28 Suppl. 1 (2004) S21-S28
6. Warmuth M., Bergmann M., Priess A., Hauslmann K., Emmerich B., and Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 272 (1997) 33260-33270
7. Sattler M., Mohi M.G., Pride Y.B., Quinnan L.R., Malouf N.A., Podar K., et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1 (2002) 479-492
8. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., and McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18 (2004) 189-218
9. Sattler M., Verma S., Byrne C.H., Shrikhande G., Winkler T., Algate P.A., et al. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol Cell Biol 19 (1999) 7473-7480
10. Martinelli G., Soverini S., Rosti G., and Baccarani M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 19 (2005) 1872-1879
11. O'Hare T., Pollock R., Stoffregen E.P., Keats J.A., Abdullah O.M., Moseson E.M., et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104 (2004) 2532-2539
12. Burgess M.R., Skaggs B.J., Shah N.P., Lee F.Y., and Sawyers C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 102 (2005) 3395-3400
13. Kimura S., Naito H., Segawa H., Kuroda J., Yuasa T., Sato K., et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106 (2005) 3948-3954
14. Golas J.M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63 (2003) 375-381
15. Campanini F., Santucci M.A., Pattacini L., Brusa G., Piccioli M., Barbieri E., et al. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia. Haematologica 86 (2001) 167-173
16. Mazzacurati L., Pattacini L., Brusa G., Mancini M., Benvenuti M., Barbieri E., et al. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. Hematol J 5 (2004) 168-177
17. Smith K.M., Yacobi R., and Van Etten R.A. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 12 (2003) 27-37
18. Chen R., Kim O., Yang J., Sato K., Eisenmann K.M., McCarthy J., et al. Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 276 (2001) 31858-31862
19. Ren S.Y., Bolton E., Mohi M.G., Morrione A., Neel B.G., and Skorski T. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences. Mol Cell Biol 25 (2005) 8001-8008
20. Hickey F.B., and Cotter T.G. BCR-ABL regulates PI3K-p110gamma transcription and activation, and is involved in increase proliferation and drug resistance. J Biol Chem 281 (2005) 2441-2450
21. Kharas M.G., and Fruman D.A. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65 (2005) 2047-2053
22. Klejman A., Rushen L., Morrione A., Slupianek A., and Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21 (2002) 5868-5876
23. Marley S.B., Lewis J.L., Schneider H., Rudd C.E., and Gordon M.Y. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Br J Haematol 125 (2004) 500-511
24. Jorgensen H.G., Allan E.K., Graham S.M., Godden J.L., Richmond L., Elliott M.A., et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19 (2005) 1184-1191
25. Tanis K.Q., Veach D., Duewel H.S., Bornmann W.G., and Koleske A.J. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol Cell Biol 23 (2003) 3884-3896
26. Park J., Hill M.M., Hess D., Brazil D.P., Hofsteenge J., and Hemmings B.A. Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity. J Biol Chem 276 (2001) 37459-37471
27. Jiang T., and Qiu Y. Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem 278 (2003) 15789-15794
28. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., and Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3 (2001) 245-252
29. Rossig L., Badorff C., Holzmann Y., Zeiher A.M., and Dimmeler S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 277 (2002) 9684-9689
30. Feng J., Tamaskovic R., Yang Z., Brazil D.P., Merlo A., Hess D., et al. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem 279 (2004) 35510-35517
31. Gesbert F., Sellers W.R., Signoretti S., Loda M., and Griffin J.D. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem 275 (2000) 39223-39230
32. Parada Y., Banerji L., Glassford J., Lea N.C., Collado M., Rivas C., et al. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem 276 (2001) 23572-23580
33. Sekimoto T., Fukumoto M., and Yoneda Y. 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27(Kip1). EMBO J 23 (2004) 1934-1942
34. Andreu E.J., Lledo E., Poch E., Ivorra C., Albero M.P., Martinez-Climent J.A., et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 65 (2005) 3264-3272
35. Hirose Y., Katayama M., Mirzoeva O.K., Berger M.S., and Pieper R.O. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 65 (2005) 4861-4869
36. Diehl J.A., Cheng M., Roussel M.F., and Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12 (1998) 3499-3511
37. Fernandez de Mattos S., Essafi A., Soeiro I., Pietersen A.M., Birkenkamp K.U., Edwards C.S., et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol 24 (2004) 10058-10071
38. Katayama K., Fujita N., and Tsuruo T. Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol Cell Biol 25 (2005) 5725-5737
39. Peters D.G., Klucher K.M., Perlingeiro R.C.R., Dessain S.K., Koh E.Y., and Daley G.Q. Autocrine and paracrine effects of an ES-cell derived, BCR-ABL-transformed hematopoietic cell line that induces leukaemia in mice. Oncogene 20 (2001) 2636-2646
40. Dorsey J.F., Cunnick J.M., Lanehart R., Huang M., Kraker A.J., Bhalla K.N., et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 16 (2002) 1589-1595
41. Wilson-Rawls J., Xie S., Liu J., Laneuville P., and Arlinghaus R.B. P21 Bcr-Abl interacts with th interleukin 3 receptor beta (c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 56 (1996) 3426-3430
42. Burton E.A., Hunter S., Wu S.C., and Anderson S.M. Binding of src-like kinases to the β-subunit of the interleukin-3 receptor. J Biol Chem 272 (1997) 16189-16195
43. Burchert A., Wang Y., Cai D., von Bubnoff N., Paschka P., Muller-Brusselbach S., et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19 (2005) 1774-1782
44. Chu S., Holtz M., Gupta M., and Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103 (2004) 3167-3174
45. Shi Y., Sharma A., Wu H., Lichtenstein A., and Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 280 (2005) 10964-10973
46. Iiyama M., Kakihana K., Kurosu T., and Miura O. Reactive oxygen species generated by hematopoietic cytokines play roles in activation of receptor-mediated signaling and in cell cycle progression. Cell Signal 18 (2006) 174-182
47. Parmar S., Katsoulidis E., Verma A., Li Y., Sassano A., Lal L., et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 279 (2004) 25345-25352
48. Khaled A.R., Bulavin D.V., Kittipatarin C., Li W.Q., Alvarez M., Kim K., et al. Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biol 169 (2005) 755-763